NEOG - CIK 0000711377
NEOGEN CORP trades as NEOG and has a market capitalization of $2.01 B, making it the #2096 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $894.66M, down 3.2% from the prior year and net income of -$1.09B. This page tracks NEOGEN CORP through 1,896 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years NEOGEN CORP's revenue grew from $321.27M to $894.66M, a compound annual growth rate of 12.1%. Net profit margin compressed from 11.4% to -122.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SD | - | 2026-05-20 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
| Major company event | 8-K | 2026-04-20 |
The largest companies sharing NEOGEN CORP's SEC industry classification (in vitro & in vivo diagnostic substances).
NEOGEN CORP (NEOG) has a market capitalization of $2.01 B as of 2026-06-10, ranking #2096 among US-listed companies.
NEOGEN CORP reported revenue of $894.66M for fiscal year 2025, a decrease of 3.2% year over year.
In its latest fiscal year NEOGEN CORP reported a net loss of $1.09B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.